Literature DB >> 3624028

Effects of fractionated schedules of irradiation combined with cis-diamminedichloroplatinum II on the SCCVII/St tumor and normal tissues of the C3H/KM mouse.

M Tanabe, D Godat, R F Kallman.   

Abstract

The interaction of cis-diamminedichloroplatinum II (c-DDP) and a course of 5 daily irradiations was investigated in the SCCVII/St tumor and normal tissues (duodenal crypt cells and lung) of the C3H mouse. Two schedules with daily doses of 2.4 mg/kg c-DDP given immediately before 4 Gy X ray on 5 consecutive days and a single 12 mg/kg c-DDP dose followed 24 hr later by the first of 5 daily 4 Gy X ray doses produced the most consistent and significant supra-additive effects on the SCCVII tumor. This supra-additive effect was also achieved with lower and much less toxic drug doses. These schedules produced high enhancement ratios (dose effect factors DEF) for mouse duodenal crypt cells, but the degree of enhancement was less than that for the SCCVII tumor. Schedules with a 72-hr interval between drug and radiation treatments, which produced low enhancement ratios for the SCCVII tumor and duodenal crypt cells, gave high enhancement ratios for the lung. It is concluded that c-DDP has the potential of enhancing the radiation effect on normal tissues, and the degree of enhancement depends upon the interval between X ray and c-DDP. The enhancement ratios for the SCCVII tumors are greater than for normal tissues, and this results in high therapeutic gain factors (TGF). Comparing the effects on tumor with those on normal tissues, it may be seen that there is clinical usefulness in simultaneous combination treatments and perhaps moreso in the administration of a single drug dose 24 hr before the first of 5 daily X ray fractions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3624028     DOI: 10.1016/0360-3016(87)90320-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

Review 1.  Strategies in the treatment of diffuse pontine gliomas: the therapeutic role of hyperfractionated radiotherapy and chemotherapy.

Authors:  M T Jennings; M L Freeman; M J Murray
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

2.  Letter in response to paper by Abratt et al., Cancer Chemother Pharmacol (1992) 30: 495.

Authors:  S Senan
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Concurrent radiation and weekly cisplatin for non-small-cell lung cancer--a phase I/II study.

Authors:  R P Abratt; P A Willcox; D G Salton
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.

Authors:  E E Vokes; J A Moormeier; M J Ratain; M J Egorin; D J Haraf; R Mick; R R Weichselbaum
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study.

Authors:  E E Vokes; D J Haraf; P C Hoffman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study.

Authors:  H J Groen; A H van der Leest; E G de Vries; D R Uges; B G Szabó; N H Mulder
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

7.  Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma.

Authors:  T Ishikawa; Y Tanaka; H Ishitsuka; T Ohkawa
Journal:  Jpn J Cancer Res       Date:  1989-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.